Core Viewpoint - The production of feed-grade vitamin E in China has shown a fluctuating upward trend, with a notable decline in 2022 due to losses in the terminal breeding industry, but a gradual recovery is expected in subsequent years [1][12]. Group 1: Industry Overview - Feed-grade vitamin E is a fat-soluble vitamin essential for animal feed, known for its antioxidant properties, which enhance meat quality, growth, and survival rates [3][12]. - The production of feed-grade vitamin E primarily relies on synthetic methods due to higher efficiency and lower costs [3][12]. Group 2: Production Trends - In 2022, China's production of feed-grade vitamin E decreased by 8.3% year-on-year, primarily due to strong cost control measures in the breeding industry [1][12]. - By 2024, the production is projected to reach 63,000 tons, reflecting a year-on-year decline of 3.2% [1][12]. Group 3: Policy Support - Various policies have been introduced to promote the development of feed-grade vitamin E, including its inclusion in the encouraged foreign investment industry directory [5][7]. - The 2025 regulatory framework includes vitamin premix feed in the supervision and inspection projects, indicating a focus on quality and safety [5][7]. Group 4: Competitive Landscape - The market features a mix of international brands like DSM and domestic companies such as Zhejiang Medicine and Xinhecheng, with the latter gaining market share through innovation [14][15]. - Emerging brands are also making their mark through differentiated competition and targeted marketing strategies [14]. Group 5: Future Trends - The demand for feed-grade vitamin E is expected to rise with the ongoing development of the global livestock industry and increased awareness of animal health [19]. - Technological innovations and sustainable production methods will drive the industry's future growth, with a focus on environmental considerations [19].

Group 1 - The company Zhejiang Shengda Bio-Pharm Co., Ltd. plans to issue shares to specific investors, with the total amount of funds raised not exceeding 267.61 million yuan [1][2] - The issuance has been approved by the Shanghai Stock Exchange and the China Securities Regulatory Commission [1][2] - The funds raised will be used for a project to produce 20,000 tons of D-isomeric ascorbic acid and its sodium salt, with a total investment of 368 million yuan [1][2] Group 2 - The issuance will involve no more than 51,356,687 shares, which is capped at 30% of the company's total share capital prior to the issuance [2][3] - The final number of shares to be issued will be determined based on the actual situation at the time of issuance [3] - Shares acquired through this issuance will be subject to a six-month lock-up period [3][4] Group 3 - The company has a plan for shareholder returns over the next three years (2023-2025), considering factors such as operational development and shareholder expectations [4] - The company will adjust the order and amount of funds allocated to projects if the actual funds raised are less than the planned investment [2][4] - The company has committed to measures to mitigate the impact of immediate return dilution on small investors [4][5] Group 4 - The company operates in the food and feed additive industry, focusing on products such as biotin and lactic acid bacteriocin [5][6] - The industry is experiencing rapid growth, but increased competition may affect profit margins [5][6] - The company has established a significant position in the market, being one of the earliest developers of biotin and biological preservatives in China [5][6]